Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.62 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026818 | 0.92 | PTGDR2 (0.66) | PTGDR2 | |
| SCHEMBL16026942 | 0.91 | PTGDR2 (0.65) | PTGDR2HSD17B10 | |
| SCHEMBL16026869 | 0.91 | PTGDR2 (0.61) | PTGDR2 | |
| SCHEMBL16026858 | 0.88 | PTGDR2 (0.61) | PTGDR2ALDH1A1 | |
| SCHEMBL16026870 | 0.87 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL16026711 | 0.80 | PTGDR2 (0.69) | PTGDR2 | |
| Bromide SCHEMBL16026795 | 0.78 | AKR1B10 (0.54) | PTGDR2AKR1B10AKR1B1MEN1ALDH1A1 | |
| SCHEMBL16026810 | 0.77 | AKR1B10 (0.48) | PTGDR2AKR1B10AKR1B1MEN1ALDH1A1 | |
| SCHEMBL2467360 | 0.77 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL16026903 | 0.77 | PTGDR2 (1.00) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558447-B1 | 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-17 | — | — | EP | disclosed |